A recent systematic review examined the use of CKIT inhibitors for unresectable or metastatic mucosal, acral, or chronically sun-damaged melanoma and reported an objective response rate of 14% in patients with mucosal melanoma, with the highest response observed with imatinib (24%) [45]. This evidence concerns the gene KIT and mucosal melanoma.